|
|
Research on application of directional penetration of traditional Chinese medicine combined with Tofacib in ankylosing spondylitis |
FU Jianping HU Juanjuan WANG Qiang |
Department of Pharmacy, Central Hospital of Xinyu Iron and Steel Group Co., Ltd., Jiangxi Province, Xinyu 338000, China |
|
|
Abstract Objective To investigate the application value of traditional Chinese medicine directional penetration combined with Tofacitb in ankylosing spondylitis. Methods From February 2018 to August 2021, 70 patients with ankylosing spondylitis admitted to the Central Hospital of Xinyu Iron and Steel Group Co., Ltd. were selected as research objects, and divided into study group (n=35) and control group (n=35) according to the random number table method. The control group was treated with conventional antirheumatic drugs, while the study group was treated with traditional Chinese medicine directional penetration combined with Tofacitinib. The clinical efficacy, scores of visual analogue scale (VAS), Bath ankylosing spondylitis metroloty index (BASMI), Bath ankylosing spondylitis functional index (BASFI), Bath ankylosing spondylitis disease activity index (BASDAI), Pittsburgh sleep quality index scale (PSQI), generic quality of life inventory-74 (GQOL-74), erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-α, interleukin-1β (IL-1β), interferon-gamma (IFN-γ), bone alkaline phosphatase (BALP), bone gamma-carboxyglutamic-acid-containing proteins (BGP), bone mineral density and total incidence of adverse reactions were compared between the two groups. Results The total effective rate of the study group was higher than that of the control group, and the difference was statistically significant (P<0.05). After 3 months of treatment, the scores of VAS, BASMI, BASFI, BASDAI and PSQI in the study group were lower than those in the control group, and the scores of GQOL-74 were higher than those in the control group, group, and the differences were statistically significant (P<0.05). After 3 months of treatment, the levels of ESR, hs-CRP, TNF-α, IL-1β and BGP in the study group were lower than those in the control group, while the levels of IFN-γ, BALP and bone mineral density were higher than those in the control group, and the differences were statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion Directional penetration of traditional Chinese medicine combined with Tofacitb in the treatment of patients with ankylosing spondylitis can improve the curative effect, enhance the spinal function, improve the quality of life and reduce the level of inflammation, which is safe and should be paid attention to clinically.
|
|
|
|
|
[1] |
赵治友,邬亚军.强直性脊柱炎中医辨证分型与风湿活动指标的相关性研究[J].中国中医药科技,2017,24(3):261-262.
|
[2] |
白如鑫,王雅慧,聂道芳,等.强直性脊柱炎中医疗法的现代机制研究进展[J].吉林中医药,2019,39(9):1247-1250.
|
[3] |
陆继清,刘建郭,卢爱华.中医定向透药疗法改善腰椎间盘突出症患者腰椎功能的疗效观察[J].中国卫生标准管理,2017,8(28):120-122.
|
[4] |
刘勇,孙俊英,王涛,等.全髋关节置换术治疗强直性脊柱炎累及髋关节的疗效观察[J].中国修复重建外科杂志,2017, 31(1):25-30.
|
[5] |
汪玉萍,王兴林,梁晓镛,等.Bath强直性脊柱炎计量指数量表的信度和敏感度研究[J].中国康复医学杂志,2003, 18(5):280-282.
|
[6] |
陈小云,张莉芸,刘雅妮.强直性脊柱炎患者疲乏症状的评定[J].中华风湿病学杂志,2008,12(5):338-341.
|
[7] |
黄旦,刘健,纵瑞凯,等.湿热型强直性脊柱炎患者氧化应激相关指标的变化及相关性研究[J].中华中医药杂志,2020,35(2):995-998.
|
[8] |
李晏,张胜利,黄烽.强直性脊柱炎患者睡眠质量及相关因素分析[J].中华风湿病学杂志,2012,16(4):251-254.
|
[9] |
曾兆良,马梁红,骆桂秀,等.综合性心理干预对甲状腺功能亢进症治疗的临床研究[J].中国心理卫生杂志,2003, 17(6):382-384.
|
[10] |
石耀武,李延红,张宏蕾,等.中医外治法治疗强直性脊柱炎性髋关节滑膜炎32例[J].现代中医药,2017,37(2):35-37.
|
[11] |
徐鹏慧、屈文龙、周惠琼.JAK抑制剂托法替布在脊柱关节炎伴外周关节病变治疗中的应用观察(附3例报告)[J].山东医药,2020,60(32):60-63.
|
[12] |
赖丽芳,沈滨华,胡爱珍.中医定向透药疗法在强直性脊柱炎关节功能恢复中的应用[J].江西中医药,2021,52(4):47-48.
|
[13] |
熊薇.补肾通督方联合中医定向透药治疗强直性脊柱炎56例观察[J].中国冶金工业医学杂志,2018,35(6):654-655.
|
[14] |
柯明珠,冯小燕,张欢欢,等.补肝益肾活血汤治疗强直性脊柱炎肝肾不足证的临床效果[J].中国当代医药,2021, 28(32):158-161.
|
[15] |
李晓昊,韦嵩,陈志煌,等.经筋微创疗法联合柳氮磺嘧啶治疗强直性脊柱炎疗效观察[J].西部中医药,2020,33(5):127-131.
|
[16] |
陈念.补肾通络法联合阿仑磷酸钠治疗强直性脊柱炎合并骨质疏松的临床效果[J].中国当代医药,2020,27(1):115-117,120.
|
[17] |
袁明权,王博,王秋霞,等.补肾中药治疗强直性脊柱炎临床疗效Meta分析[J].西部中医药,2020,33(11):76-85.
|
[18] |
袁晓航.中药川乌与草乌的鉴别比较及药理活性探究[J].内蒙古中医药,2017,36(18):137-138.
|
[19] |
袁海建,李卫,金建明,等.桂枝汤化学成分,药理作用机制与临床应用研究进展[J].中国中药杂志,2017,42(23):4556-4564.
|
|
|
|